Braveheart Bio director granted 30,000 stock options

Braveheart Bio, Inc. reported that director and 10% owner Erez Chimovits received a grant of 30,000 stock options to acquire Braveheart Bio common stock at an exercise price of $18.00 per share.

Rhea-AI Filing Summary

Braveheart Bio, Inc. reported that director and 10% owner Erez Chimovits received a grant of 30,000 stock options to acquire Braveheart Bio common stock at an exercise price of $18.00 per share. These options, which now total 30,000 derivative securities held directly, expire on August 4, 2036. The shares underlying the option will vest in full on the earlier of August 5, 2027 or the date of the company’s next annual stockholders’ meeting, subject to his continued service. Under a separate agreement, any securities or economic benefits from these options are to be transferred to OrbiMed Advisors LLC for the benefit of OrbiMed Private Investments IX, LP.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Chimovits Erez

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 contracts (Direct)

Footnotes (2)

1. F1. The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
2. F2. Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP.

Key Figures

Options granted: 30,000 options Exercise price: $18.00 per share Expiration date: August 4, 2036 +2 more

5 metrics

Options granted 30,000 options Stock Option (Right to Buy) grant to Erez Chimovits on 2026-08-05

Exercise price $18.00 per share Conversion or exercise price of stock options

Expiration date August 4, 2036 Option expiration for the 30,000 stock options

Post-transaction derivative holdings 30,000 options Total derivative securities held directly after the grant

Vesting date trigger August 5, 2027 Latest date when options vest, or earlier at next annual meeting

Key Terms

Stock Option (Right to Buy), vesting, economic benefit, derivative securities

4 terms

Stock Option (Right to Buy) financial

"security_title is listed as Stock Option (Right to Buy)"

vesting financial

"The shares underlying the stock option will vest in full upon the earlier"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

economic benefit financial

"or the economic benefit thereof to OrbiMed Advisors LLC"

derivative securities financial

"total_shares_following_transaction shows 30,000 derivative securities"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Erez Chimovits report on this Form 4 for BRVE?

Erez Chimovits reported a grant of 30,000 stock options for Braveheart Bio, Inc. common stock. The options were acquired at an exercise price of $18.00 per share and are held as derivative securities directly.

What are the vesting terms of the 30,000 stock options reported for BRVE?

The 30,000 options will vest in full on the earlier of August 5, 2027 or the date of Braveheart Bio’s next annual stockholders’ meeting. Vesting is subject to Erez Chimovits’ continued service with the company through the vesting date.

What is the exercise price and expiration date of the BRVE options granted?

The options carry an exercise price of $18.00 per share and an expiration date of August 4, 2036. After this expiration date, any unexercised portion of the 30,000 options will no longer be exercisable.

Who ultimately receives the economic benefit of the BRVE options granted to Erez Chimovits?

Under an agreement with OrbiMed Advisors LLC, Erez Chimovits must transfer any securities or economic benefit from these options to OrbiMed Advisors LLC, which will ensure they are provided to OrbiMed Private Investments IX, LP.

How many Braveheart Bio derivative securities does Erez Chimovits hold after this option grant?

Following this transaction, Erez Chimovits is reported as directly holding 30,000 derivative securities in the form of stock options. These options each relate to one share of Braveheart Bio common stock upon exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/11/2026 - 08:04 PM Accepted by SEC EDGAR 08/07/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chimovits Erez

(Last) (First) (Middle)

C/O BRAVEHEART BIO, INC.

ONE LETTERMAN DR., BLDG. A, SUITE A4-300

(Street)

SAN FRANCISCO CALIFORNIA 94129

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Braveheart Bio, Inc. [ BRVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18	08/05/2026		A		30,000		(1)	08/04/2036	Common Stock	30,000	$0	30,000	D(2)

Explanation of Responses:

1. The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

2. Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP.

Remarks:

	/s/ James Paul Rickey, Attorney-in-Fact	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)